SoftBank mulling $150M investment in Science 37: report by Conor Hale Wednesday, June 6, 2018 SoftBank is considering a $150 million investment in siteless trial runner Science 37, the latest in a string of biotech deals, according to reports.
FierceMedTech’s 2017 Fierce 15 by Amirah Al Idrus Monday, December 11, 2017 Genomics, bioelectronics and artificial intelligence are clear themes among FierceMedTech's 2017 Fierce 15 companies.
Guardant sues Foundation Medicine over false advertising by Amirah Al Idrus Friday, June 23, 2017 Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition.
Guardant gets $360M to sequence 1M cancer patients by Nick Paul Taylor Friday, May 12, 2017 Guardant Health has raised $360 million to sequence the tumor DNA of 1 million cancer patients in the next five years.
Liquid biopsy play Freenome bags $65M in a16z-led round by Nick Paul Taylor Wednesday, March 1, 2017 Freenome has raised $65 million in a round led by Andreessen Horowitz to put its cancer-detection tests through more rigorous trials.
Guardant, MD Anderson ink multiyear liquid biopsy deal by Amirah Al Idrus Wednesday, February 1, 2017 Guardant Health and the University of Texas MD Anderson Cancer Center aim to to push liquid biopsy into the standard of care in cancer treatment.
Guardant Health buoyed by positive study results for liquid biopsy testing by Emily Wasserman Monday, September 12, 2016 Guardant Health is celebrating study results showing that its liquid biopsy tests may work better than standard tissue biopsy in advanced lung cancer patients who can’t undergo traditional testing.
